We specifically investigated the effect of lenalidomide on XBP1-specific memory CD8+ CTL against breast cancer, colon cancer and pancreatic cancer cells, which overexpress XBP1 unspliced and spliced antigens. The gene discussed is CD8A; the disease is malignant colon neoplasm.